Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA , whose protein product is reduced in autistic brain
Authors:
Open Access
- 7 April 2010
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 24 (8) , 3036-3051
Abstract
Autism is currently considered a multigene disorder with epigenetic influences. To investigate the contribution of DNA methylation to autism spectrum disorders, we have recently completed large‐scale methylation profiling by CpG island microarray analysis of lymphoblastoid cell lines derived from monozygotic twins discordant for diagnosis of autism and their nonautistic siblings. Methylation profiling revealed many candidate genes differentially methylated between discordant MZ twins as well as between both twins and nonautistic siblings. Bioinformatics analysis of the differentially methylated genes demonstrated enrichment for high‐level functions including gene transcription, nervous system development, cell death/survival, and other biological processes implicated in autism. The methylation status of 2 of these candidate genes, BCL‐2 and retinoic acid‐related orphan receptor alpha ( RORA ), was further confirmed by bisulfite sequencing and methylation‐specific PCR, respectively. Immunohistochemical analyses of tissue arrays containing slices of the cerebellum and frontal cortex of autistic and age‐ and sex‐matched control subjects revealed decreased expression of RORA and BCL‐2 proteins in the autistic brain. Our data thus confirm the role of epigenetic regulation of gene expression via differential DNA methylation in idiopathic autism, and furthermore link molecular changes in a peripheral cell model with brain pathobiology in autism.—Nguyen, A., Rauch, T. A., Pfeifer, G. P., Hu, V. W. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA , whose protein product is reduced in autistic brain. FASEB J . 24, 3036–3051 (2010). www.fasebj.orgKeywords
Funding Information
- Autism Speaks (2381)
- National Institutes of Health (R21 MH073393)
- National Institute of Mental Health (1U24MH081810)
This publication has 65 references indexed in Scilit:
- Genomic and epigenetic evidence for oxytocin receptor deficiency in autismBMC Medicine, 2009
- Gene expression profiling differentiates autism case–controls and phenotypic variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in severe autismAutism Research, 2009
- Altered gene expression and function of peripheral blood natural killer cells in children with autismBrain, Behavior, and Immunity, 2009
- Methyl‐CpG‐binding protein 2 polymorphisms and vulnerability to autismGenes, Brain and Behavior, 2008
- Epigenetic mechanisms and the transgenerational effects of maternal careFrontiers in Neuroendocrinology, 2008
- Abnormal melatonin synthesis in autism spectrum disordersMolecular Psychiatry, 2007
- 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disordersHuman Molecular Genetics, 2007
- Non‐coding RNAs in the nervous systemThe Journal of Physiology, 2006
- Genomic DNA methylation: the mark and its mediatorsTrends in Biochemical Sciences, 2006
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001